DaVita Inc. (DVA)
NYSE: DVA · Real-Time Price · USD
149.76
+0.93 (0.62%)
At close: Mar 19, 2026, 4:00 PM EDT
149.76
0.00 (0.00%)
After-hours: Mar 19, 2026, 4:15 PM EDT
DaVita Revenue
In the year 2025, DaVita had annual revenue of $13.64B with 6.46% growth. DaVita had revenue of $3.62B in the quarter ending December 31, 2025, with 9.87% growth.
Revenue (ttm)
$13.64B
Revenue Growth
+6.46%
P/S Ratio
0.73
Revenue / Employee
$174,911
Employees
78,000
Market Cap
10.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.64B | 827.52M | 6.46% |
| Dec 31, 2024 | 12.82B | 675.40M | 5.56% |
| Dec 31, 2023 | 12.14B | 530.25M | 4.57% |
| Dec 31, 2022 | 11.61B | -8.90M | -0.08% |
| Dec 31, 2021 | 11.62B | 68.19M | 0.59% |
| Dec 31, 2020 | 11.55B | 162.13M | 1.42% |
| Dec 31, 2019 | 11.39B | -16.37M | -0.14% |
| Dec 31, 2018 | 11.40B | 528.22M | 4.86% |
| Dec 31, 2017 | 10.88B | 169.17M | 1.58% |
| Dec 31, 2016 | 10.71B | 725.22M | 7.27% |
| Dec 31, 2015 | 9.98B | -2.81B | -21.98% |
| Dec 31, 2014 | 12.80B | 1.03B | 8.76% |
| Dec 31, 2013 | 11.76B | 3.58B | 43.70% |
| Dec 31, 2012 | 8.19B | 1.45B | 21.61% |
| Dec 31, 2011 | 6.73B | 512.20M | 8.24% |
| Dec 31, 2010 | 6.22B | 118.96M | 1.95% |
| Dec 31, 2009 | 6.10B | 440.48M | 7.78% |
| Dec 31, 2008 | 5.66B | 396.02M | 7.52% |
| Dec 31, 2007 | 5.26B | 383.49M | 7.86% |
| Dec 31, 2006 | 4.88B | 1.91B | 64.12% |
| Dec 31, 2005 | 2.97B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fresenius Medical Care AG | 23.05B |
| Tenet Healthcare | 21.31B |
| Universal Health Services | 17.36B |
| Encompass Health | 5.94B |
| Option Care Health | 5.65B |
| PACS Group | 5.29B |
| The Ensign Group | 5.06B |
| Brookdale Senior Living | 3.05B |
DVA News
- 1 day ago - DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement - PRNewsWire
- 2 days ago - R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease - GlobeNewsWire
- 17 days ago - DaVita Inc. (DVA) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 23 days ago - DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference - PRNewsWire
- 5 weeks ago - 20 stocks of companies that delivered a double dose of growth this earnings season - Market Watch
- 6 weeks ago - DaVita Stock Rallies On Profit Beat, Confident 2026 View - Benzinga
- 6 weeks ago - DaVita: Some Success Is Possible, But Volatility Is Still Heavy - Seeking Alpha
- 6 weeks ago - DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript - Seeking Alpha